Vaneltix Pharma, Inc.

NEW BRUNSWICK, NJ · Biotech · Private

Pharmaceutical treatments for interstitial cystitis and bladder pain syndrome

Claim this profile

Follows are private to you and power your alerts

Updated · vaneltix.com

Sector
Biotech
Headquarters
NEW BRUNSWICK, NJ
Latest Form D
$1M, Jan 2024
Total capital
$6.9M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$6.9M
6 Form D · last Jan 2024
33 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
1
1 pending · first 2025
Rank in peer group#481 of 1449

Capital timeline

201320152017201920212023FEDERAL ↑EQUITY ↓Cumulative $6.9M1st Form D$750K3rd Form D$500K4th Form D$1.4M5th Form D$3M6th Form D$1M
201320152017201920212023FEDERAL ↑EQUITY ↓Cumulative $6.9M

Latest events

  • Private capital raisedForm D · SEC · 6th filing$1M
  • Private capital raisedForm D · SEC · 5th filing$3M
  • Private capital raisedForm D · SEC · 4th filing$1.4M
  • Private capital raisedForm D · SEC · 3rd filing$500K
  • Private capital raisedForm D · SEC · 2nd filing$300K
  • Private capital raisedForm D · SEC · 1st filing$750K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 1449 peers

Line = median

Biotech · Molecule

  • Granted patents#481 · top 33%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings
  • Carlo Lowell Di FonzoDirectorNamed in SEC Form D filings
  • C. Lowell ParsonsDirectorNamed in SEC Form D filings
  • Daniel VickeryExecutive Officer, DirectorNamed in SEC Form D filings
  • Robert Lowell EvansDirectorNamed in SEC Form D filings

What it has protected

USPTO · 1 granted of 2

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .